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Aim: To test ocellatin peptides (ocellatins-PT2-PT6) for antibacterial and antibiofilm activities and synergy 
with antibiotics against Pseudomonas aeruginosa. Materials & methods: Normal- and checkerboard-broth 
microdilution methods were used. Biofilm studies included microtiter plate-based assays and microscopic 
analysis by confocal laser scanning microscopy and atomic force microscopy. Results: Ocellatins were more 
active against multidrug-resistant isolates of P. aeruginosa than against susceptible strains. Ocellatin-PT3 
showed synergy with ciprofloxacin and ceftazidime against multidrug-resistant isolates and was capable 
of preventing the proliferation of 48-h mature biofilms at concentrations ranging from 4 to 8x the MIC. 
Treated biofilms had low viability and were slightly more disaggregated. Conclusion: Ocellatin-PT3 may 
be promising as a template for the development of novel antimicrobial peptides against P. aeruginosa. 
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Antimicrobial resistance (AMR) is one of the greatest threats  to health  today  [I,2] . It can affect anyone,  at any 
age, in any country. It is of consensus that the threat of drug resistance can only be tackled with the right set of 
actions, including the development of novel treatment options and alternative antimicrobial therapies [3]. Gram­ 
negative pathogens are of particular concern since they are becoming resistant to nearly all the antibiotic drug 
options available, in fact, infections by pandrug­resistant Gram­negative bacilli are rising [4]. The most worrisome 
Gram­negative infections are commonly caused by Enterobacteriaceae (mostly Klebsiella pneumoniae), Pseudomonas 
aeruginosa and Acinetobacter spp. [5]. 
P aeruginosa is a ubiquitous microorganism that commonly causes hospital­acquired infections, including 
pneumonia, bloodstream and urinary tract infections and it is well known for chronically colonizing the respiratory 
tract of patients with cystic fibrosis, causing severe intermittent exacerbation of the condition [6]. P aeruginosa 
infections are particularly difficult to control because of its high level of intrinsic resistance to antibiotics due 
primarily to a combination of the impermeable outer membrane and a number of broad­spectrum efflux pumps [7]. 
Some strains of P aeruginosa have been found to be multidrug­resistant (MDR), with resistance to nearly all 
antibiotics, including aminoglycosides, cephalosporins, Buoroquinolones and carbapenems [5]. Moreover, this 
Gram­negative bacterium is capable of forming structured aggregates known as biofilms, which definitely contribute 
to the increase of both pathogenicity and resistance to antibiotic treatment [8,9]. Biofilm formation by P aeruginosa 
is the result of a complex adaptation process driven by genetic variation and the qualitative composition of the 
polysaccharide content in the biofilm matrix is highly dependent on phenotypic features including the ability to 
synthesize high amounts of alginate (mucoid strains) or Psl/ Pel (nonmucoid strains) [IO]. Indeed, biofilms of P 
aeruginosa are one of the bottlenecks in the treatment of such infections . Therefore, there is an urgent need of novel 
antimicrobial agents and treatment strategies able to effectively counteract planktonic as well as biofilm modes of 
growth. 
Antimicrobial peptides (AMPs) historically have been called defensive molecules, and are believed to be the first 
line of the innate immune response system against viruses, bacteria and fungi [I I,12]. Natural AMPs can be found 
in every organism from prokaryotes to eukaryotes (protozoan, fungi, plants, insects and animals) [I I]. 
In the last few years, many AMPs have been reported as promising novel antimicrobial drugs due to their 
main mechanisms of action, which include disrupting membranes, interfering with metabolism, and targeting 
cytoplasmic components [13]. Additionally, AMPs are increasingly being considered as novel agents against biofilms 
by inhibiting the biofilm formation or eradicating established biofilms [14,15]. 
Another approach to overcome the problem of MDR bacteria is by combining different drugs. The combination 
of AMPs with commercially available antibiotics have also been explored as a potential alternative for combating 
drug­resistant infections caused by several microorganisms  [16­18]. 
In this study, five peptides ­ ocellatin­PT2­PT6 ­ previously isolated from the skin secretion of the frog 
Leptodactylus pustulatus  [19]  were tested for antimicrobial activity and synergistic effects with antibiotics against 
P aeruginosa. The peptides herein studied were part  of a set of eight new AMPs, called  ocellatins, which had 
been isolated from the crude skin secretion of L. pustulatus, identified and tested for antimicrobial activity against 
Escherichia coli, Staphylococcus aureus, K pneumoniae and Salmonella choleraesuis strains by Marani et al. [19]. 
Moreover, those ocellatins were reported  to present little or no hemolytic activity against human erythrocytes and 
no cytotoxicity  against murine fibroblasts. 
Recently, several frog skin­derived AMPs have been largely reported to show antibacterial properties [20­23]. There 
have also been reports of antibiofilm activity from some such molecules [15]. Therefore, the skin secretions from 
many species of anurans are a rich source of peptides with antimicrobial activities that should be explored for 
further research and development of novel therapeutic agents. 
 
 
 
 
 
 .   Table Amino acid sequence and molecular weight of ocellatin-PT2-PT6. 
Peptides Sequence MW Ref. 
Ocellatin-PT2 GVFDllKDAGKQLVAHATGKIAEK  vt 2609.0 [19] 
Ocellatin-PT3 GVIDllKGAGKDLIAHAIGKLAEKV  1 2530.0 [19] 
Ocellatin-PT4 GVFDllKGAGKQLIAHAMGKIAEKV  1 2595.1 [19] 
Ocellatin-PT5 GVFDllKDAGRQLVAHAMGKIAEKV  1 2667.1 [19] 
Ocellatin-PT6 GVFDllKGAGKQLIAHAMEKIAEKVGLNKDGN 3365.9 [19] 
t c-terminus-amidated  peptide. 
MW: Molecular weight. 
 
Materials & methods 
Antimicrobial agents & ocellatin peptides 
Standard laboratory powders of ceftazidime and ciproB.oxacin hydrochloride were purchased from Sigma­Aldrich 
(MO, USA). All the antibiotic discs used were from Oxoid (Basingstoke, England). The five ocellatin peptides 
(ocellatin­PT2­PT6), whose amino acid sequences are shown in Table 1, were manually synthesized, purified 
and quantified through slightly different protocols than those previously described [19]. The peptides were syn­ 
thesized using the Merrifield solid phase synthesis techniques on a 24 channel multiplex Symphony® peptide 
synthesizer (Gyros Protein Technologies, Inc, AZ, USA) and were assembled using 0­(6­chlorobenzotriazol­l­yl)­ 
N,N,N',N'­tetramethyluronium hexaB.uorophosphate and N,N­diisopropylethylamine­coupling conditions. The 
full and detailed protocol of synthesis and purification is provided as supplementary material. All peptides were 
dissolved in Milli­Q water to obtain stock solutions of 10 mg/ ml. 
 
Bacterial strains & growth conditions 
P. aeruginosa ATCC 27853, P. aeruginosa PAOl and a susceptible clinical isolate, PA007, as well as MDR clinical 
isolates of P. aeruginosa (Pal­SA2, Pa4­SA2 and PA006) were used in this study. The AMR profile of MDR isolates 
is shown in Supplementary Table 1. These bacteria were grown on Mueller­Hinton (MH) agar (Liofilchem srl, 
Roseto degli Abruzzi [Te], Italy) from stock cultures. MH plates were incubated at 37°C prior to obtain fresh 
cultures for each in vitro bioassay. 
 
MIC & MBC determination 
The minimum inhibitory concentration (MIC) values of the five ocellatins, ceftazidime and ciproB.oxacin against P. 
aeruginosa isolates were determined by the broth microdilution method, following the recommendations contained 
in the Clinical and Laboratory Standards Institute (CLSI) guidelines [24], with  the exception  that MH  broth was 
used instead of cation­adjusted MH broth. The MIC was defined as the lowest concentration that completely 
inhibited the growth of bacteria as detected by the naked eye. The minimum bactericidal concentration (MBC) was 
determined by spreading 10 µl on MH agar from the wells corresponding to/ and above the MIC showing no visible 
growth, with further incubation for 24 h at 37°C; the lowest concentration at which  no bacterial growth occurred 
on MH plates was defined as the MBC. These experiments were performed  in three independent  experiments. 
 
Synergy testing 
The disc­diffusion method on agar was used as a screening test to assess the combined effect between ocellatins 
and antibiotics. MDR P. aeruginosa isolates from fresh cultures in MH were suspended in buffered peptone water 
(Oxoid) in order to reach a turbidity equal to a 0. 5 McFarland standard and spread on MH agar plates. CiproB.oxacin 
and ceftazidime discs were used as controls and were also impregnated with 15 µl of a 10­mg/ ml solution of each 
peptide. The plates were incubated overnight at 37°C. Potential synergism was inferred when the zone of inhibition 
caused by the antibiotic discs impregnated with ocellatins was greater  than the inhibition zone produced by the 
antibiotic discs or peptide­impregnated  blank discs alone. 
Based on the results of the previous assay, potential synergism observed between ocellatins, particularly ocellatin­ 
PT3 and ocellatin­PT4, and antibiotics (ciproB.oxacin or ceftazidime), was then checked using a broth microdilution 
checkerboard method and tested against Pa4­SA2 and Pal­Sa2 as previously described [25]. Three independent 
experiments were carried out. The fractional inhibitory concentrations (FIC) were calculated and interpreted as 
stated by Gomes et al. [25]. BrieB.y, FIC of drug A (FIC A) = MIC of drug A in combination/MIC of drug A alone, 
and FIC of drug B (FIC B) = MIC of drug B in combination/MIC of drug B alone. The FIC index (I;FIC) is the 
 
 
sum of each FIC and is interpreted as follows: I;FIC :S 0.5, synergy; 0.5 < I;FIC :S 4, indifference; 4 < I;FIC, 
antagonism. 
 
Biofilm inhibition assay 
Given the promising antibacterial activity of ocellatin­PT3 against P. aeruginosa isolates, its ability to inhibit the 
biofilm formation was assessed. Ocellatin­PT3  at concentrations  equal to MIC,  l /2 x  MIC,  l /4 x  MIC and l/8 x 
MIC was added to bacterial suspensions of 1 x 106 CFU/ml in tryptic soy broth. Bacterial suspensions without 
ocellatin­PT3 were used as controls. Each suspension was dispensed into a 96­well microtiter plate (200 µI/well) 
and incubated at 37°C for 48 h. After that time, biofilms were stained with 0.5% crystal violet for 5 min, rinsed with 
water, air dried and eluted with acetic acid 33% (v/ v). The optical density was measured at 
595 nm. 
 
Biofilm treatment assay 
The efficacy of ocellatin­PT3 on established biofilm of P. aeruginosa was also assessed by obtaining the minimum 
biofilm inhibitory concentration (MBIC). Briefly, biofilms were allowed to form for 48 h in 96­well microtiter plates, 
then the planktonic phase were discarded and the biofilms were rinsed twice and further treated with different concentrations 
of ocellatin­PT3 ranging from the MIC value up to 12x MIC. The optical density (OD)6oo was immediately measured 
and measured again after 24 h of incubation at 37°C. The MBIC was defined as the lowest concentration of ocellatin 
inhibiting the bacterial proliferation  in the planktonic phase, confirmed by no increase or :::;10% increase in the optical 
density compared with the initial reading [26]. 
 
Evaluation of biofilm metabolic activity 
48­h biofilms of Pal­SA2, Pa4­SA2 and PA006 formed as described above in 96­well microtiter plates were 
subsequently treated with ocellatin­PT3 at a concentration equivalent to the respective MBIC. After 24 h of 
incubation at 37°C, the bacterial metabolic activity of biofilms was quantified using the 3­(4,5­dimethylthiazol­2­ yl)­
2,5­diphenyltetrazolium bromide ­ MTT (0.5 mg/ml; Sigma­Aldrich) for 3 h at 37°C in the dark. Dimethyl sulfoxide 
(DMSO) was used to extract the formazan dye product and then absorbance at 570 nm was measured. 
 
Confocal laser scanning microscopy 
For confocal laser scanning microscopy (CLSM) analysis, 48­h biofilms of Pal­SA2, Pa4­SA2 and PA006 were 
formed in µ­Dish (35 mm, high), ibidi Polymer Coverslips (ibidi GmbH, Planegg­Martinsried, Germany) from 
starting inocula of 1 x  106 CFUIml in tryptic soy broth. After 48 h, biofilms were rinsed twice with phosphate­ 
buffered saline and treated with a concentration of ocellatin­PT3 equal to the respective MBIC for 24 h. Biofilms were 
then rinsed and stained using the live/ dead staining BacLight bacterial viability kit (Molecular Probes, Thermo Fisher 
Scientific, MA, USA). Biofilms were examined by a widefield fluorescence microscope Zeiss Axiolmager Zl equipped 
with a Plan­Apochromat 63x /1.40 Oil DIC objective and a camera Axiocam  MR ver.3.0 (Carl Zeiss, Oberkochen, 
Germany) and by a laser scanning confocal system Leica TCS SP5 II using a HC PL APO CS 63x /1.30 Glycerine 21°C 
objective (Leica Microsystems, Wetzlar, Germany). All experiments were performed at room temperature, and each 
chamber slides was used for no longer than 10 min. 
As for the viability cell counts, the proportion oflive and dead cells was determined by counting six representative images 
taken from each biofilm visualized, using software Image analysis [27]. 
 
Atomic  force  microscopy  imaging 
48­h biofilms of Pal­SA2, Pa4­SA2 and PA006 were formed on a glass coverslip previously put inside 35­mm 
diameter polystyrene plates and treated with or without ocellatin­PT3 as above described for CLSM. Biofilms formed on the 
coverslips were rinsed with sterile phosphate­buffered saline and dried before atomic force microscopy (AFM) imaging. 
Samples were scanned with a TT­AFM from AFMWorkshop in air in vibrating mode. A 50­µm scanner and 300 kHz 
silicon cantilevers (ACT, AppNano, CA, USA) were used. Images were processed using Gwyddion 
2.47 software. 
 
Conformational analysis of ocellatin-PT3 by circular dichroism 
The secondary structure content of ocellatin­PT3 was assessed by circular dichroism (CD) spectroscopy in the far 
UV, using a Jasco J­815 CD Spectropolarimeter QASCO) as previously reported [28]. Briefly, the measurements 
 
 
 
  Table 2. Minimum inhibitory concentration and minimum bactericidal concentration values (fig/ml) of ocellatins against  
susceptible and multidrug-resistant Pseudomonas aeruginosa.  
Peptides P. aeruginosa ATCC P. aeruginosa PAQ11 PA0071 (MIC [MBC]) Pa4-SA21 (MIC [MBC])    Pa1-SA21 (MIC [MBC])    PA0061 (MIC [MBC]) 
278531 (MIC [MBC]) (MIC [MBC]) 
Ocellatin-PT2 1024 (>1024) 512 (>1024) 1024 (>1024) 128 (256) 256 (512) 16 (32) 
Ocellatin-PT3 >512 (-) 512 (>1024) 1024 (>1024) 64 (128) 128 (256) 16 (16) 
Ocellatin-PT4 >512 (-) 512 (>1024) 1024 (>1024) 256 (256) 512 (1024) 16 (32) 
Ocellatin-PT5 >512 (-) 512 (>1024) 1024 (>1024) 128 (256) 256 (512) 32 (64) 
Ocellatin-PT6 1024 (>1024) 512 (>1024) 1024 (>1024) 128 (256) 256 (512) 32 (64) 
!Susceptible. 
1Multidrug-resistant. 
MBC: Minimum bactericidal concentration;  MIC: Minimum inhibitory concentration. 
 
were carried out under a nitrogen gas Bow of 8 l/ h at 20°C. Spectra were obtained between 190 and 260 nm. 
The lipopolysaccharides (LPS) from P. aeruginosa were obtained from Sigma­Aldrich. Ocellatin­PT3 was used in a 
concentration of lOO µM and the LPS in concentrations of O, 0.50, 0.75 and 1.00% (p/ v) in Milli­Q water. These 
experiments were performed  at 37°C and a scan speed of 50 nm/ min, a response  time of 1 s and a bandwidth  of 
1 nm were used. The spectra were converted to molar ellipticity per residue as previously reported  [28,29]. 
 
Statistical analysis 
The biofilm inhibition and treatment assays as well as the biofilm metabolic activity assay were carried out in 
two independent experiments, being each experiment performed in triplicate. The results of the biofilm formation 
were expressed as mean values ± standard deviation. The statistical significance of differences between controls 
and experimental groups was evaluated using Student's t-test. Probability values (p) of < 0.05 were considered 
statistically significant. 
 
Results 
Antibacterial  activity of ocellatin  peptides against  P. aeruginosa 
MIC values of ocellatins were initially determined against a P. aeruginosa ATCC 27853 and an MDR isolate, Pa4­
SA2. Interestingly, the MIC and MBC values were lower against Pa4­SA2 than against the reference strain. 
Therefore, subsequently, we have determined the MIC of that ocellatin against other two non­MDR (susceptible) 
and two MDR P. aeruginosa isolates (Table 2). Ocellatin­PT3 was the most active among the five peptides with 
lower MIC and MBC values. As shown, the activity against the clinical isolate PA006 was particularly strong, the 
highlight  being the bactericidal  activity of ocellatin­PT3 at only 16 µg/ ml. 
 
Synergy between ocellatins & antibiotics 
The screening for potential synergy between ocellatins and antibiotics against MDR P. aeruginosa isolates revealed 
that the combinations of ocellatin­PT3/ceftazidime and ocellatin­PT3/ciproBoxacin increased (by 3­4 mm) the 
zones of inhibition in comparison to the zones caused  by each compound alone. Equally, the combinations 
ocellatin­PT4/ceftazidime and ocellatin­PT4 also increased growth inhibition (by 2­3 mm) compared with single 
components. Photos of the combined effect between ocellatins and antibiotics against Pa4­SA2 can be seen in 
Supplementary Figure 1. Those combinations were further tested using a checkerboard method. Only the synergies 
between ocellatin­PT3/ceftazidime and ocellatin­PT3/ciproBoxacin were confirmed (FIC index :::;0.5; Table 3). 
 
Antibiofilm activities of ocellatin-PT3 
The ability of ocellatin­PT3 to inhibit the biofilm formation by Pa4­SA2 and PA006 isolates was examined 
(Figure 1). In presence of concentrations equal to the MIC and l /2 x MIC, less biofilm biomass was quantified. 
However, at lower subinhibitory concentrations more biofilm was formed compared with the control. 
The MBIC of ocellatin­PT3 against 48­h established biofilms formed by the three MDR isolates are shown in 
Table 4. The concentrations of ocellatin­PT3 that could inhibit the proliferation of mature biofilms ranged from 4 
to lO x the respective MIC values. The relative MBIC of ciproBoxacin was considerably higher than that recorded 
for this peptide. For instance, when a 48­h biofilm of Pa4­SA2 was treated with a concentration 32 x MIC of 
E 
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    Table 3. MIC values of ocellatins-PT3 and -PT4 in combination with antibiotics and respective fractional  inhibitory 
 concentration index values obtained from the checkerboard method.  
MOR isolate  MIC (µgLml)  l:FIC 
Alone  In  combination 
PT3 CIP PT3 CIP 
Pa4-SA2 64 32 8 4 0.25 
Pa1-SA2 128 16 16 4 0.38 
PT3 CAZ. PT3 CAZ. 
Pa4-SA2 64 32 16 4 0.38 
Pa1-SA2 128 16 32 4 0.5 
PT4 CIP PT4 CIP 
Pa4-SA2 256 32 128 8 0.75 
PT4 CAZ. PT4 CAZ. 
Pa4-SA2 256 32 128 16 1.00 
1FIC :s0.5, synergy; 0.5 < 1FIC :s 4, indifference; 4 < 1FIC, antagonism. 
CAZ: Ceftazidime; C IP: Ciprofloxacin; FIC: Fractional inhibitory concentration; MDR: Multidrug-resistant; MIC: Minimum inhibitory concentration; PT3: Ocellatin-PT3; PT4: Ocellatin-PT4. 
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Figure 1.   Biomass quantification of biofilms of Pseudomonas aeruginosa Pa4-Sa2 and PAOOG. Biofilms were formed 
in the presence of different concentrations of ocellatin-PT3 (ranging from  1/ B x  MIC to MIC). Differences between the 
experimental  group and the control were  statistically  significant  for  a  *p  < 0.05. 
MIC: Minimum inhibitory concentration. 
 
 
    Table 4. Minimum biofilm inhibitory concentration (fig/ml) values against 48-h preformed biofilms of 
 multidrug-resistant Pseudomonas aeruginosa isolates.  
Pa4­SA2 Pa1­SA2 PA006 
Ocel latin-PT3 512 (8 x MIC) 512 (4 x MIC) 160 (10 x MIC) 
Ciprofloxaci n >1024 (>32 x MIC) >512 (>32 x MIC) >64 (>32 x MIC) 
MIC: Minimum inhibitory concentration. 
 
ciproB.oxacin, there still was an increase of 48% in the optical density after 24 h. Therefore, although the amount 
of peptide required to inhibit biofilm growth was quite high, it compares favorably to the conventional antibiotic. 
 
Metabolic activity of biofilms 
The metabolic activity of 48­h biofilms treated for 24 h with ocellatin­PT3 at concentrations equivalent to the 
respective MBIC was reduced by almost 70% (Figure 2). Differences between ocellatin­PT3­treated biofilms and 
controls were statistically significant (p < 0.001). 
 
Ocellatin-PT3 effect on biofilm after microscopic analyses 
The CLSM images (Figure 3) showed, for all three isolates, a clear effect of ocellatin­PT3 in lowering the viability of 
IPa4-SA2 
IPA006 
..· 
GI 
0
 
 
 
 
 
0 
.?:' ·:; 
u _ 20 
Ill 
.2 e..... 
o g  40 
.1c11   ­ 
(,) ::I 
E "O      60 
E !!! 
;;:::: 80 ijj 
100 
 
 
Pa1-SA2 Pa4-SA2 PA006 
 
 
Figure 2.   Metabolic activity reduction of Pseudomonas aeruginosa biofilms after treatment with ocellatin-PT3. 48-h 
preformed biofilms of Pa1-SA2, Pa4-SA2 and PA006 were treated for 24 h with a concentration of ocellatin-PT3 
corresponding to the respective minimum biofilm inhibitory concentration . The metabolic activity was assessed 
through the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide (MTT) assay. Differences were statistically 
significant in relation to the control for a ***p < 0.001 . 
 
 
the bacterial cells within the biofilm. A slight disaggregating effect in the biofilm's structure could also be perceived. 
Additionally, AFM images (Figure 4) of the biofilms formed and treated in the same conditions as for CLSM 
analysis reflect also a disaggregating effect on the biofilm caused by the ocellatin­PT3 as well as a direct effect on 
bacterial cells, which  became more wrinkled and seem hollow. In some cases, for example, in the left image in 
Figure 4A, showing the Pal­SA2 strain under control conditions, single cells were hard to distinguish from each 
other. This is normal, since AFM only shows the upper surface of the biofilm, which for mature biofilms typically 
consist more of the polymeric matrix than individual cells. However, after treatment, this biofilm also showed 
exposed cells, which would further reduce the viability of the biofilm. 
 
Second ary structu ra l stud ies 
Ocellatin­ PT3 secondary structures were studied using CD spectroscopy in both the absence and presence of 
increasing amounts of LPS (Figure 5). This study not only evaluates the structure of the AMP in the solution 
but also shows its activity against P. aeruginosa by interacting with the LPS. The first peak exhibited a Amax at 
approximately 198 nm and double Amin at approximately 210 and 225 nm. CD measurements of ocellatin­PT3 
in water and 0.5% of LPS indicate a random conformation with a minimum close to 198 nm. Nevertheless, when 
the LPS concentration increases, the shape of CD spectra suggests the predisposition to form defined secondary 
structures. The CD spectrum at 1.00% of LPS presents one maximum at 192 nm and two minima around 207 and 
222 nm, which are characteristic of a­helix structures. The estimated helicities indicated 39% for ocellatin­PT3 in 
the presence of LPS membrane lipid. 
 
Discussion 
AMPs have been largely explored in order to assess their possible use as alternatives to conventional antimicrobial 
agents. In particular, AMPs derived from frog skin secretions have been the focus of many studies lately, being 
isolated from frogs belonging to different families, genus and species, and most of them endemic of a particular 
region in the world [30­32] . Skin secretions of the frog L. pustulatus (found in the central Brazilian cerrado biome) 
furnished a set of AMPs, named ocellatins that differ only in a few amino acid substitutions [19] . Although those 
ocellatins had shown low antimicrobial activity against E. coli ATCC 25922, S. aureus ATCC 29313, K pneumoniae 
ATCC 700603, S. choleraesuis ATCC 14028, five of them (ocellatin­PT2­PT6) have now shown to be more active 
against P. aeruginosa, especially against MDR isolates of that bacterial species. Others have also described a particular 
AMP, T9W, to have strong and specific activity against P. aeruginosa and low or no activity against other Gram­ 
negative and Gram­positive bacteria [33]. The explanation for the higher activity of ocellatins against drug­resistant 
isolates than against susceptible strains may be related to membrane permeability / impermeability. It is known that 
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Figure 3.   Confocal laser scanning microscopy qualitative evaluation of Pseudomonas aeruginosa biofilms not treated (controls) and treated with 
ocellatin-PT3. 48-h preformed biofilms of Pa1-SA2 (A), Pa4-SA2 (B) and PA006 (C) were treated for 24 h with a concentration of ocellatin-PT3 
corresponding to the respective minimum biofilm inhibitory concentration. All biofilms, after live/dead staining, show viable (green fluorescence) 
and dead (red fluorescence) cells. Percentages of viable and dead cells are also shown; the values are the means ± standard deviation obtained from 
the counts of six representative images taken from each biofilm that was visualized . 
 
 
permeability mutations are responsib le for increasing the resistance to many classes of antimicrobials (­lactams, 
Buoroquinolones, aminoglycosides) in P. aeruginosa [34], therefore, those mutations, present in the MDR isolates, 
may revert a natural impermeability to ocellatins, suggesting that the development of resistance to known antibiotics 
and to ocellatins may be mechanistically independent. Such hypothesis may also explain why the MIC values of 
ocellatin­PT3 were a little variable depending on the MDR isolate. 
The proximity of MBC values to those of MIC (MBC values were equally or twofold higher than the MIC) may 
foreshadow the bactericidal effect of ocellatins. 
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Figure 4.   Atomic force microscopy images of Pseudomonas aeruginosa biofilms not treated (A) and treated (B) with ocellatin-PT3. 48-h 
preformed biofilms of Pa1-SA2, Pa4-SA2 and PA006 were treated for 24 h with a concentration of ocellatin-PT3 corresponding to the 
respective minimum biofilm inhibitory concentration. 
 
 
A plausible and accepted strategy to treat drug­resistant­associated infections is using a combination  of antimi­ 
crobial agents, particularly with different mechanisms of action, which would hamper the emergence of resistance. 
It was therefore appropriate to test ocellatins for potential synergy with different classes of conventional antibiotics 
against P. aeruginosa. Since the treatment of P. aeruginosa infections are very challenging, due to their intrinsic 
resistance to multiple antimicrobials [7], a new agent that can revert the installed resistance to a particular antibiotic 
might hold promise for novel antipseudomonal therapies. Among the five ocellatin  peptides tested, ocellatin­PT3 
acted synergistically with ceftazidime and ciproBoxacin against MDR isolates. The mechanisms behind these syn­ 
ergies must be further explored, however, hypothetically, we can suppose ocellatin­PT3 can increase the membrane 
permeability allowing the entrance of the antibiotic into the cell. Moreover, since the MIC of ocellatin­PT3, when 
in combination, was lowered itself, it may indicate that the antibiotic may also potentiate  other mechanism  of 
action of ocellatin­PT3,  probably at the cytoplasmic level. 
The growing interest in biofilm treatment by AMPs has been notorious in the recent years. In fact, a database 
gathering AMPs active on biofilms was created in 2015 [14,35]. Many AMPs have been reported to prevent biofilm 
formation and/ or to eradicate established biofilms, and in some cases the mechanisms beyond those antibiofilm 
effects have been disclosed or hypothesized [9,15,36]. Herein, we have demonstrated the antibiofilm activity of 
ocelatin­PT3. 
The ability ofocellatin­PT3 to prevent the biofilm formation by MDR P. aeruginosa isolates was not marked, since 
in the presence of l /2 x MIC a biofilm could be formed even if its biomass was not as abundant as in the respective 
control biofilm. Moreover, for lower concentrations (l/4 x MIC and 1/8x MIC) even more biofilm biomass was 
quantified  in comparison  to the control biofilm. Therefore, ocellatin­PT3 may not present  an interesting potential 
to hamper P. aeruginosa biofilm formation. 
Nevertheless, its effects on established biofilms were more promising. Ocellatin­PT3 was able to inhibit the 
proliferation of 48­h mature biofilms in concentrations up to lO x MIC. In the same conditions, ciproBoxacin 
could not hamper the biofilm proliferation even when present in a concentration of 32 x MIC (at this concentration, 
 
 
 
 
 
 
 
Figure 5.  Conformational analysis of ocellatin-PT3 by circular dichroism. (A) Circular dichroism spectra of 
ocellatin-PT3  in aqueous solution (red line) as well as in the presence of LPS in many concentrations. (B) Schematic 
representation of the behavior of ocellatin-PT3  in the presence of LPS corroborating  with the circular dichroism 
experiment. 
LPS: Lipopolysaccharide . 
 
 
it only reduced in about 50% the proliferation of the biofilm). Indeed, it is commonly accepted that biofilms are 
more tolerant to antibiotics than are planktonic cells [37]. 
We could also observe that biofilms treated with ocellatin­PT3 in a concentration equal to the MBIC had a much 
lower metabolic activity (around 70% less activity in respect to controls). One could suppose that the reduction 
of metabolic activity may be due to cell death, nevertheless, in the case of biofilms, that correlation cannot be 
so straightforward, since biofilm­associated bacterial cells can enter a reversible dormant status, in which cells are 
metabolically inactive [38]. Therefore, in order to explore the effects of ocellatin­PT3 on the biofilms viability, 
CLSM was used in conjunction with the live/ dead­staining technique, revealing in fact a marked decrease in the 
viability of bacterial cells within the ocellatin­PT3­treated biofilms. Indeed, it has been suggested that AMPs that 
can reduce or eradicate mature biofilms at concentrations equal or higher than their MIC against the corresponding 
planktonic cells, are very likely to act by a classical bactericidal effect [9] . 
The effects of AMPs on the surface structure of microorganisms can be related to their affinities to the lipid 
composition of the membrane: prokaryotic and eukaryotic membranes vary considerably in lipid contents [28] . 
Anionic lipids are exposed at the surface of many bacterial membranes. Importan tly, P. aeruginosa colonization 
of host tissues is triggered by an initial attachment of the bacterium to epithelial cells, via a variety of surface 
appendages (e.g., flagella, pili). This is then followed by cell internalization, presumab ly mediated by the bacterial 
 
 
 
 
 
LPS (i.e., the major component of the outer membrane in Gram­negative bacteria) [39]. In the presence of LPS 
isolated from P. aeruginosa, the CD spectra of ocellatin­PT3 exhibit helical­like features. Recent studies concluded 
that cationic peptides can act on Gram­negative bacteria through interaction with LPS [40]. In brief, ocellatin­PT 
peptides present a solvent (e.g., 2,2,2­triBuoroet hanol [TFE]) and/or LPS­dependent helix structure adoption that 
suggests a change in confirmation upon interaction with microorganisms [28]. Hence, the CD results suggest an 
interaction between ocellatin­PT3 and LPS isolated from P. aeruginosa that may represent the begin ning of the 
mechanism of bactericidal action. 
Apart from CLSM, biofilms formed and treated in similar conditions were also visualized by AFM. Notewort hy, 
the only difference in the preparation of the biofilms for these two techniques regarded the supporting material 
used for the formation of the biofilms that was ibidi Polymer Coverslips for the CLSM and glass coverslips for 
AFM. As shown in Figures 3 and 4, a bigger biofilm was formed by Pa4­SA2 on the glass coverslip (AFM image) 
in comparison to the one formed in the ibidi coverslip. Therefore, it was evident that the type of material had 
influence on the adhesion of Pa4­SA2 cells, consequently affecting the quantity and type of biofilm formed. While 
for the other two isolates, the type of supporting material apparently did not account for substantial differences in 
the biofilms formed. 
CLSM and AFM are microscopic techniques widely used in biofilm research as they offer the unique possibility 
to obtain valuable information on the biofilm structure and organization. In fact, the microscopic analyses showed 
that ocellatin­PT3  could also affect the biofilms structure, by causing a slight disaggregation. The mechanism 
beyond this effect can only be speculated at this point; for instance, it may be due to interference with regulatory 
signals or interference with the accumulation of matrix components  [9]. 
 
Conclusion & future perspective 
Over the last years, AMPs have gained increasing attention as potential novel antimicrob ial drugs alternatives for 
combating infections caused by antibiotic­resistant bacteria and/ or associated to biofilms. Thus, new AMPs with 
such potential must be reported and fu rther explored to create advances in the overall goal to overcome the problem 
of AMR. 
Ocellatin­PT3 may be promising as a lead molecule for the design and development of novel AMPs with 
significant activity and selectivity against MDR P. aeruginosa biofilms. 
 
 
 
 
 
 
 
 
 
 
Summary points   
• In this study, five ocellatin peptides, originally isolated from the skin secretion of Leptodactylus pustulatus, were 
explored for their potential use against the opportunistic pathogen Pseudomonas aeruginosa . 
• The ocellatins tested were more active against multidrug-resistant P. aeruginosa  isolates than against susceptible 
strains. 
• Ocellatin-PT3 showed synergistic effects with ciprofloxacin and ceftazidime, which might hold promise for 
developing future combinatorial therapies after uncovering the mechanisms triggering such synergy. 
• Ocellatin-PT3 could inhibit the proliferation of established biofilms at concentrations from 4 to 10x the MIC, 
which was mostly due to a direct killing effect on the bacterial cells within the biofilm as shown by confocal laser 
scanning microscopy after live/dead staining . 
• Atomic force microscopy images of ocellatin-PT3-treated biofilms also reveal membrane alteration of P. 
aeruginosa cells. 
• Conformational analysis by circular dichroism of ocellatin-PT3  in the presence of lipopolysaccharide  (LPS) let 
foresee that such peptide interacts with the LPS isolated from P. aeruginosa . 
• Interaction with lipopolysaccharides may constitutes the the initial step of its main mechanism of action that is 
likely to be the disruption of the cell membrane integrity. 
• Ocellatin-PT3 may be explored for the design and development of novel antimicrobial peptides. 
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